Poster: Increased sensitivity and differentiation of pTau 217 and Neurofilament light using SPEAR technology

This poster discusses the use of ultrasensitive immunoassay platforms to reveal the clinical potential of blood-based protein biomarkers of Alzheimer’s Disease, detecting them at low fg/mL levels for early prognosis, screening, and therapy monitoring. However, conventional technologies face limited adoption due to specialized equipment needs, reagent immobilization, and high sample volume requirements. The study demonstrates the ability of SPEAR technology to detect and differentiate Neurofilament light, pTau 217, and pTau 231 at sub fg/mL levels from sub-microliter samples, meeting the demand for ultra-sensitive biomarker analysis with non-invasive, small-volume sample collection and accessible platforms for frequent monitoring and high-throughput assay performance.

Authors: Tsz Wing Fan, WonHee Kim, Corinne Thomas, Wenjing Jiang, Jeremy Tan and Feng Xuan, Spear Bio Inc, Woburn, MA, USA